Christopher Joseph Soares

US Patent:

6479492, Nov 12, 2002

Filed:

Jan 21, 2000

Appl. No.:

09/489378

Inventors:

Andrei W. Konradi - San Francisco CA
Michael A. Pleiss - Sunnyvale CA
Eugene D. Thorsett - Half Moon Bay CA
Susan Ashwell - Plainsboro NJ
Dimitrios Sarantakis - Newtown PA
Gregory S. Welmaker - Jackson NJ
Anthony Kreft - Langhorne PA
Christopher Semko - Fremont CA
Robert Warren Sullivan - Oceanside CA
Christopher Joseph Soares - La Jolla CA
Kiev Sui Ly - San Diego CA
Christine M. Tarby - Hockessin DE

Assignee:

Elan Pharmaceuticals, Inc. - So. San Francisco CA

International Classification:

A61K 3153

US Classification:

514241, 514245, 544180, 544194, 544204, 544217, 544220

Abstract:

Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e. g. , human, such as asthma, Alzheimers disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

US Patent:

6903088, Jun 7, 2005

Filed:

Aug 15, 2002

Appl. No.:

10/218445

Inventors:

Andrei W. Konradi - San Francisco CA, US
Michael A. Pleiss - Sunnyvale CA, US
Eugene D. Thorsett - Half Moon Bay CA, US
Christopher Semko - Fremont CA, US
Robert Warren Sullivan - Oceanside CA, US
Christopher Joseph Soares - La Jolla CA, US
Kiev Sui Ly - San Diego CA, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA
Wyeth - Madison NJ

International Classification:

A61K031/33
A61K031/44
C07D213/02

US Classification:

514183, 514352, 514 1, 546304, 546307, 546329, 546345

Abstract:

Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e. g. , human, such as asthma, Alzheimer's disease, antherosclerosis. AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

US Patent:

7538215, May 26, 2009

Filed:

Jun 2, 2005

Appl. No.:

11/145489

Inventors:

Andrei W. Konradi - San Francisco CA, US
Michael A. Pleiss - Sunnyvale CA, US
Eugene D. Thorsett - Half Moon Bay CA, US
Christopher Semko - Fremont CA, US
Christopher Joseph Soares - La Jolla CA, US
Christine M. Tarby - Hockessin DE, US

Assignee:

Elan Pharmaceuticals, Inc. - South San Francisco CA
Wyeth - Madison NJ

International Classification:

C07D 239/02
C07D 237/00
C07D 415/00

US Classification:

544330, 544327, 544328, 544329, 544332

Abstract:

Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e. g. , human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

US Patent:

8076288, Dec 13, 2011

Filed:

Aug 17, 2005

Appl. No.:

11/206903

Inventors:

Odile Esther Levy - San Diego CA, US
Michael R. Hanley - Corte Madera CA, US
Carolyn M. Jodka - Encinitas CA, US
Diana Y. Lewis - San Diego CA, US
Christopher J. Soares - La Jolla CA, US
Soumitra S. Ghosh - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
David G. Parkes - Del Mar CA, US
Christine M. Mack - San Diego CA, US

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 38/00
A61K 38/26

US Classification:

514 72, 514 68

Abstract:

The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

US Patent:

8114958, Feb 14, 2012

Filed:

Feb 11, 2005

Appl. No.:

10/589054

Inventors:

Christopher J. Soares - La Jolla CA, US
Michael R. Hanley - Corte Madera CA, US
Diana Y. Lewis - San Diego CA, US
David Geoffrey Parkes - Del Mar CA, US
Carolyn M. Jodka - Encinitas CA, US
Kathryn S. Prickett - Foster City CA, US
Soumitra S. Ghosh - San Diego CA, US
Christine Marie Mack - San Diego CA, US
Qing Lin - Getzville NY, US

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

C07K 19/00
C07K 14/435
A61K 38/16
A61P 3/04

US Classification:

530307, 530324, 514 49, 514 119, 514909, 536 234

Abstract:

The present invention relates to obesity related polypeptides (ORPs), related nucleic acids, expression constructs, host cells, and processes production of the obesity related polypeptides. The ORPs of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.

US Patent:

8263545, Sep 11, 2012

Filed:

Aug 17, 2007

Appl. No.:

11/840921

Inventors:

Odile Esther Levy - San Diego CA, US
Alain D. Baron - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
Mary Erickson - San Diego CA, US
Soumitra S. Ghosh - San Diego CA, US
Michael R. Hanley - San Diego CA, US
Samuel Janssen - San Diego CA, US
Carolyn M. Jodka - San Diego CA, US
Diana Y. Lewis - San Diego CA, US
Christine M. Mack - San Diego CA, US
David G. Parkes - San Diego CA, US
Richard A. Pittner - San Diego CA, US
Christopher J. Soares - San Diego CA, US
Ved Srivastava - San Diego CA, US
Andrew A. Young - San Diego CA, US
Thao Le - San Diego CA, US

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 38/00
A61P 3/10

US Classification:

514 11, 514 68, 514 117

Abstract:

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

US Patent:

8404637, Mar 26, 2013

Filed:

Feb 10, 2006

Appl. No.:

11/816095

Inventors:

Odile Esther Levy - San Diego CA, US
Alain D. Baron - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
Mary Erickson - San Diego CA, US
Soumitra S. Ghosh - San Diego CA, US
Michael R. Hanley - San Diego CA, US
Samuel Janssen - San Diego CA, US
Carolyn M. Jodka - San Diego CA, US
Diana Y. Lewis - San Diego CA, US
Christine M. Mack - San Diego CA, US
David G. Parkes - San Diego CA, US
Richard A. Pittner - San Diego CA, US
Christopher J. Soares - San Diego CA, US
Ved Srivastava - San Diego CA, US
Andrew A. Young - San Diego CA, US

Assignee:

Amylin Pharmaceuticals, LLC - San Diego CA

International Classification:

A61K 38/00
A61P 3/10

US Classification:

514 72, 514 68

Abstract:

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

US Patent:

8497240, Jul 30, 2013

Filed:

Aug 17, 2007

Appl. No.:

12/377856

Inventors:

Odile Esther Levy - San Diego CA, US
Alain D. Baron - San Diego CA, US
Lawrence J. D'Souza - San Diego CA, US
Mary Erickson - San Diego CA, US
Soumitra S. Ghosh - San Diego CA, US
Michael R. Hanley - Corte Madera CA, US
Samuel Janssen - San Marcos CA, US
Carolyn M. Jodka - Encinitas CA, US
Diana Y. Lewis - San Diego CA, US
Christine M. Mack - San Diego CA, US
David G. Parkes - Del Mar CA, US
Richard A. Pittner - Palo Alto CA, US
Christopher J. Soares - La Jolla CA, US
Ved Srivastava - Cary NC, US
Andrew A. Young - Chapel Hill NC, US
Thao Le - Carlsbad CA, US

Assignee:

Amylin Pharmaceuticals, LLC - San Diego CA
AstraZeneca Pharmaceuticals LP - Wilmington DE

International Classification:

A61K 38/00
A61K 38/16
A61K 38/26

US Classification:

514 69, 514 213, 514 72, 514 117, 530324, 530308

Abstract:

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.